🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in the EU / 2025-524987-39-00
Completed Phase I

A Phase 1b, Double-Blind Study to Investigate Safety, Tolerability, Pharmacokinetics, Efficacy, and Pharmacodynamics of Single Dose of ATI-052 in Participants with Mild to Moderate Asthma

2025-524987-39-00 · tracked via the Priya Life Science EU tracker
Sponsor
Aclaris Therapeutics Inc.
Sponsor type
Pharmaceutical company
Therapeutic area
Respiratory Tract Diseases
Decision date
16/04/2026
Enrollment target
10
Sites
Germany

Condition studied

Mild to Moderate Asthma

Eligibility

Age group
65+ years, 18-64 years
Sex
Female, Male
Official registry record

This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View 2025-524987-39-00 on CTIS ↗ ← All trials in the EU